ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether certain statements issued by Trevena, Inc. (“Trevena” or the “Company”) (NASDAQ: TRVN) complied with federal securities laws. On February 21, 2017, Trevena announced the clinical trial results for its morphine-alternative drug, Oliceridine, which revealed that the drug did not have statistically significant rates of higher tolerability or safety as compared to standard morphine. The price of TRVN common stock fell significantly following the announcement.
If you purchased Trevena common stock between January 19, 2016 and February 17, 2017 and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com or Marshall P. Dees, Esq. at firstname.lastname@example.org, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.